Cargando…

Pridopidine activates neuroprotective pathways impaired in Huntington Disease

Pridopidine has demonstrated improvement in Huntington Disease (HD) motor symptoms as measured by secondary endpoints in clinical trials. Originally described as a dopamine stabilizer, this mechanism is insufficient to explain the clinical and preclinical effects of pridopidine. This study therefore...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geva, Michal, Kusko, Rebecca, Soares, Holly, Fowler, Kevin D., Birnberg, Tal, Barash, Steve, -Wagner, Avia Merenlender, Fine, Tania, Lysaght, Andrew, Weiner, Brian, Cha, Yoonjeong, Kolitz, Sarah, Towfic, Fadi, Orbach, Aric, Laufer, Ralph, Zeskind, Ben, Grossman, Iris, Hayden, Michael R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291233/ https://www.ncbi.nlm.nih.gov/pubmed/27466197 http://dx.doi.org/10.1093/hmg/ddw238

Ejemplares similares

Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse
por: Kusko, Rebecca, et al.
Publicado: (2018)

Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids
por: Kolitz, Sarah, et al.
Publicado: (2015)

Letter to the Editor response: Nygaard et al.
por: Towfic, F., et al.
Publicado: (2017)

Metoprolol‐pridopidine drug–drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease
por: Rabinovich‐Guilatt, Laura, et al.
Publicado: (2017)

A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis
por: Ross, Colin J., et al.
Publicado: (2017)

Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington’s Disease
por: Waters, Susanna, et al.
Publicado: (2018)

Leveraging existing data sets to generate new insights into Alzheimer’s disease biology in specific patient subsets
por: Fowler, Kevin D., et al.
Publicado: (2015)

Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date
por: Squitieri, Ferdinando, et al.
Publicado: (2015)

Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study
por: McGarry, Andrew, et al.
Publicado: (2020)

Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose
por: Darpo, Borje, et al.
Publicado: (2023)

Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19)
por: Kim, Jason, et al.
Publicado: (2020)

Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1(G93A) Model
por: Ionescu, Ariel, et al.
Publicado: (2019)

The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease
por: Rabinovich‐Guilatt, L., et al.
Publicado: (2015)

Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson’s Disease
por: Francardo, Veronica, et al.
Publicado: (2019)

Neuroprotection of retinal ganglion cells by the sigma-1 receptor agonist pridopidine in models of experimental glaucoma
por: Geva, Michal, et al.
Publicado: (2021)

Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1/sigma-1 receptor chaperone by pridopidine
por: Wang, Shao-Ming, et al.
Publicado: (2022)

Pridopidine for the Improvement of Motor Function in Patients With Huntington's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Chen, Shujun, et al.
Publicado: (2021)

Pridopidine Reverses Phencyclidine-Induced Memory Impairment
por: Sahlholm, Kristoffer, et al.
Publicado: (2018)

Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [(18)F] fluspidine and [(18)F] fallypride PET study
por: Grachev, Igor D., et al.
Publicado: (2020)

Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model
por: Squitieri, Ferdinando, et al.
Publicado: (2015)

Comparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic
por: Towfic, Fadi, et al.
Publicado: (2014)

Pridopidine modifies disease phenotype in a SOD1 mouse model of amyotrophic lateral sclerosis
por: Estévez‐Silva, Héctor M., et al.
Publicado: (2022)

Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses
por: Sahlholm, Kristoffer, et al.
Publicado: (2015)

Pridopidine Promotes Synaptogenesis and Reduces Spatial Memory Deficits in the Alzheimer’s Disease APP/PS1 Mouse Model
por: Estévez-Silva, Héctor M., et al.
Publicado: (2022)

Response to the Letter-to-the Editor by Cohen et al. concerning our eNeurologicalSci article, Melamed-Gal, et al. Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone. eNeurologicalSci 2018;12:19–30.https://doi.org/10.1016/j.ensci.2018.05.006
por: Melamed-Gal, Sigal, et al.
Publicado: (2018)

Impairment and Restoration of Homeostatic Plasticity in Cultured Cortical Neurons From a Mouse Model of Huntington Disease
por: Smith-Dijak, Amy I., et al.
Publicado: (2019)

B-cell Ligand Processing Pathways Detected by Large-scale Comparative Analysis
por: Towfic, Fadi, et al.
Publicado: (2012)

Characterizing patient compliance over six months in remote digital trials of Parkinson’s and Huntington disease
por: Cohen, Shani, et al.
Publicado: (2018)

Population Pharmacokinetic Modeling and Simulation of TV‐46000: A Long‐Acting Injectable Formulation of Risperidone
por: Perlstein, Itay, et al.
Publicado: (2022)

BioNetwork Bench: Database and Software for Storage, Query, and Analysis of Gene and Protein Networks
por: Kohutyuk, Oksana, et al.
Publicado: (2012)

Large Roads Reduce Bat Activity across Multiple Species
por: Kitzes, Justin, et al.
Publicado: (2014)

An Australian Neuro-Palliative perspective on Huntington's disease: a case report
por: Shah, Rajvi, et al.
Publicado: (2021)

Utility of the Huntington's Disease Prognostic Index Score for a Perimanifest Clinical Trial
por: Langbehn, Douglas R., et al.
Publicado: (2022)

Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone
por: Melamed-Gal, S., et al.
Publicado: (2018)

Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma
por: Flynt, Erin, et al.
Publicado: (2020)

Repaired tetralogy of Fallot: the roles of cardiovascular magnetic resonance in evaluating pathophysiology and for pulmonary valve replacement decision support
por: Geva, Tal
Publicado: (2011)

Defining the Transcriptional and Cellular Landscape of Type 1 Diabetes in the NOD Mouse
por: Carrero, Javier A., et al.
Publicado: (2013)

Correction: Defining the Transcriptional and Cellular Landscape of Type 1 Diabetes in the NOD Mouse
por: Carrero, Javier A., et al.
Publicado: (2014)

The Israeli National Committee for sex selection by pre-implantation genetic diagnosis: a novel approach (2005–2011)
por: Pessach, Nirit, et al.
Publicado: (2014)

Observing Huntington’s Disease: the European Huntington’s Disease Network’s REGISTRY
por: Orth, Michael, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_o1b57t6nvi57fm8q42d3iqjlib